Johnson & Johnson (J&J) reported on April 24, 2026, that it has entered into an agreement to acquire Atraverse Medical, a company in the cardiovascular medical device sector, for an undisclosed amount. The deal would further expand J&J into the cardiovascular treatment market.
Atraverse Medical developed the HOTWIRE™ system, the first and only transseptal system with impedance-guided shutoff. The HOTWIRE™ system is a novel radiofrequency (RF) guidewire that enables zero exchange left-heart access while acting as a rail for catheter-based therapy systems. Dr. Devi Nair, Director of Cardiac Electrophysiology at St. Bernards stated:
In its press release, Atraverse Medical noted that “[g]aining safe and precise access to the left atrium remains one of the most critical steps in both electrophysiology and structural heart interventions” and “the challenges and risks associated with needle-based left-heart access have been a frustration.” Dr. Mark Metzl , Section Chief, Cardiac Electrophysiology at Endeavor Health stated that “[t]he fully-integrated HOTWIRE™ system meets these needs head on and delivers control, visibility, and efficiency – simplifying the process and improving workflow in our centers.”
J&J stated in its press release, that “[t]he planned acquisition of Atraverse Medical would strengthen Johnson & Johnson’s portfolio of cardiac ablation solutions, bringing electrophysiologists innovative tools to treat patients with atrial fibrillation and other cardiac arrhythmias.” This deal marks J&J’s latest cardiovascular medtech acquisition in the last few years following the acquisition of Abiomed for $16.6 billion in 2022, the acquisition of Laminar, Inc. (operating now under Biosense Webster) for $400 million in 2023, the acquisition of Shockwave Medical for $13.1 billion in 2024, and the acquisition of V-Wave for $600 million in 2024.
Subscribe for News and Updates
